FLOROPTIC

(Fluorometholone)

Sterile Ophthalmic Suspension &
Sterile Gama Irradiated Ophthalmic Ointment

Suspension
Composition:
Each ml contains:
Fluorometholone .....1 mg.
(U.S.P Specifications)
Preservative: Benzalkonium chloride.
Vehicle: hydroxypropyl methyl cellulose.

Ointment
Composition:
Each gram contains:
Fluorometholone .....1 mg.
(U.S.P Specifications)

Actions:
Inhibition of the inflammatory response, to inciting agent of mechanical, chemical or immunological nature. No generally accepted explanation of this steroid property has been advanced. However, corticosteroids arc thought to act by the induction of phospholipase A_2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and Ieukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholoipase A_2 Adrcnocorticosteroids and their derivatives arc capable of producing a rise in intra ocular pressure. In clinical studies on patients eyes treated with both Dexamethasone and Fluorometholone, Fluorometholone demonstrated a lower propensity to increase intra ocular pressure than did Dexamethasone.

Indications:
For steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornca and anterior segment of the globe.

Dosage and Administration:
Suspension
1 to 2 drops instilled into the conjunctival sac (s) four times daily. During the initial 24 to 48 hours the dosage may be safely increased to two drops every two hours. If no improvement after two weeks, consult physician. Care should be taken not to discontinue therapy prematurely.

Ointment
Apply a small amount (app.½) inch ribbon into the concunctival sac(s) one to three times daily. During the initial 25-48hrs the freq. of dosing may be increased to one application very four hours. May aid in the establishment of secondary ocular infection from fungi or viruses liberated from ocular tissues. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. use of topical corticosteriods in the presence of thin corneal or scleral tissue may lead to perforation. Safety and effectiveness have not been demonstrated in children of the age group of 2 years or below. Safety of the use of topical steroids during pregnancy has not been established. As the fungal infections of the cornea are particularly prone to develop coincidentally with long term local steroid applications, fungus invasion must be suspected in any persistent conreal ulceration where a steroid has been used or in use. Intra ocular pressure should be checked frequently.

Adverse reactions:
Elevation of intra ocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsullar cataract formation, secondary ocular infection from pathogens liberated from ocular tissues, perforation of the globe and delayed wound healing.

How Supplied:
SUSPENSION
As 5ml sterile ophthalmic suspension in plastic dropper bottles.

OINTMENT
Floroptic 0.1% ophthalmic ointment is supplied as pack of 3.5 grams in tube.

Warning
Do not touch the tube tip to any surface since it may contaminate the ointment.

Storage:
Store below 30°C.
Protect from heat and sunlight.
Keep out of the reach of children
For ophthalmic use only.
Use within four weeks after first opening the bottle.
Shake well before use.

خوراک: ڈاکٹر کی ہدایات کی مطابق استعمال کریں۔
ہدایات: دوا کو دھوپ اور گرمی سے بچائیں۔
۳۰ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔
تمام ادویات بچوں کی پہنچ سے دور رکھیں۔
پہلی دفعہ بوتل کھولنے کے بعد دوا کو چار ہفتوں تک استعمال کیا جا سکتا ہے۔
استعمال سے پہلے اچھی طرح ہلا لیں۔

Manufactured by:
Vega Pharmaceuticals (Pvt.) Ltd.
30 Km, Multan Road, Lahore, Pakistan.